Sandra Gardiner compensation by year
NEKTAR THERAPEUTICS Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $0 | $0 | $0 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 |
| Option awards | $0 | $0 | $0 |
| Non-equity incentive | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $376,300 | $460,850 | $686,400 |
| Total | $376,300 | $460,850 | $686,400 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NEKTAR THERAPEUTICS DEF 14A filed April 24, 2026, accession 0001140361-26-016708, and prior-year filings. Open the filing on EDGAR.
Change-in-control & termination
estimated payments NEKTAR THERAPEUTICS discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $0 | $0 | $0 | $0 |
Per the Potential Payments Upon Termination or Change in Control table in NEKTAR THERAPEUTICS's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
NEKTAR THERAPEUTICS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Howard Robin | President and Chief Executive Officer | $6,256,954 |
| Jonathan Zalevsky | Chief Research and Development Officer | $2,320,358 |
| Sandra Gardiner · this page | Interim Chief Financial Officer | $686,400 |
| Mark Wilson | Former Chief Legal Officer | $667,901 |
The full NEKTAR THERAPEUTICS compensation record
free company briefThis page is one person within NEKTAR THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order NEKTAR THERAPEUTICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NEKTAR THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat